Genome-wide microarray analysis of gene expression profiling in major depression and antidepressant therapy

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4:64:334-40. doi: 10.1016/j.pnpbp.2015.02.008. Epub 2015 Feb 20.

Abstract

Major depressive disorder (MDD) is a serious health concern worldwide. Currently there are no predictive tests for the effectiveness of any particular antidepressant in an individual patient. Thus, doctors must prescribe antidepressants based on educated guesses. With the recent advent of scientific research, genome-wide gene expression microarray studies are widely utilized to analyze hundreds of thousands of biomarkers by high-throughput technologies. In addition to the candidate-gene approach, the genome-wide approach has recently been employed to investigate the determinants of MDD as well as antidepressant response to therapy. In this review, we mainly focused on gene expression studies with genome-wide approaches using RNA derived from peripheral blood cells. Furthermore, we reviewed their limitations and future directions with respect to the genome-wide gene expression profiling in MDD pathogenesis as well as in antidepressant therapy.

Keywords: Antidepressants; Genome-wide gene expression profiling; Genome-wide microarray analysis; Major depressive disorder; Transcriptional profiling.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antidepressive Agents / therapeutic use*
  • Biomarkers / metabolism
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / metabolism*
  • Gene Expression / drug effects
  • Gene Expression Profiling / methods*
  • Humans
  • Microarray Analysis / methods*
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Biomarkers